Terry-Ann Burrell - Jun 14, 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Nathan Hatfield, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Jun 14, 2022
Transactions value $
$0
Form type
4
Date filed
6/16/2022, 08:12 PM
Previous filing
Apr 5, 2022
Next filing
Jul 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +18.1K +13.31% $0.00 155K Jun 14, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (right to buy) Award $0 +36.3K $0.00 36.3K Jun 14, 2022 Class A Common Stock 36.3K $6.20 Direct
holding RXRX Stock Option (right to buy) 12.5K Jun 14, 2022 Class A Common Stock 12.5K $18.00 Direct
holding RXRX Stock Option (right to buy) 405K Jun 14, 2022 Class A Common Stock 405K $2.22 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 14, 2023 or the day prior to the Issuer's 2023 annual meeting of stockholders.
F2 One forty-eighth (1/48th) of the shares subject to the award (524,999 total options granted) shall vest one month after April 29, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.